KR20220113700A - 가족성 자율신경실조증 치료를 위한 화합물 - Google Patents

가족성 자율신경실조증 치료를 위한 화합물 Download PDF

Info

Publication number
KR20220113700A
KR20220113700A KR1020227019352A KR20227019352A KR20220113700A KR 20220113700 A KR20220113700 A KR 20220113700A KR 1020227019352 A KR1020227019352 A KR 1020227019352A KR 20227019352 A KR20227019352 A KR 20227019352A KR 20220113700 A KR20220113700 A KR 20220113700A
Authority
KR
South Korea
Prior art keywords
methyl
chloro
amine
pyrimidin
thieno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227019352A
Other languages
English (en)
Korean (ko)
Inventor
난징 장
마이클 에이. 아놀드
아말 다카
그레이 미첼 카프
톰 투안 루엉
크리스 모릴
자나 나라심한
니콜라이 에이. 나리쉬킨
앤서니 터포프
지아쉬 왕
샤오옌 장
Original Assignee
피티씨 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피티씨 테라퓨틱스, 인크. filed Critical 피티씨 테라퓨틱스, 인크.
Publication of KR20220113700A publication Critical patent/KR20220113700A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
KR1020227019352A 2019-12-12 2020-12-07 가족성 자율신경실조증 치료를 위한 화합물 Ceased KR20220113700A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962947049P 2019-12-12 2019-12-12
US62/947,049 2019-12-12
PCT/US2020/063612 WO2021118929A1 (en) 2019-12-12 2020-12-07 Compounds for treating familial dysautonomia

Publications (1)

Publication Number Publication Date
KR20220113700A true KR20220113700A (ko) 2022-08-16

Family

ID=74046197

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227019352A Ceased KR20220113700A (ko) 2019-12-12 2020-12-07 가족성 자율신경실조증 치료를 위한 화합물

Country Status (14)

Country Link
US (1) US20230057568A1 (https=)
EP (1) EP4072677A1 (https=)
JP (2) JP2023506488A (https=)
KR (1) KR20220113700A (https=)
CN (1) CN115209955A (https=)
AU (1) AU2020402717A1 (https=)
BR (1) BR112022011364A2 (https=)
CA (1) CA3160053A1 (https=)
CL (1) CL2022001523A1 (https=)
CO (1) CO2022008195A2 (https=)
IL (1) IL293764A (https=)
MX (1) MX2022007094A (https=)
PE (1) PE20221581A1 (https=)
WO (1) WO2021118929A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108519TA (en) 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
MX2024002887A (es) * 2021-09-07 2024-05-28 Ptc Therapeutics Inc Metodos para tratar enfermedades neurodegenerativas.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1028964A1 (en) * 1997-11-11 2000-08-23 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
WO2005007083A2 (en) * 2003-06-18 2005-01-27 Smithkline Beecham Corporation Chemical compounds
JP2009007341A (ja) * 2007-06-01 2009-01-15 Mitsubishi Tanabe Pharma Corp 医薬組成物
EP2014663A1 (de) * 2007-07-12 2009-01-14 Bayer Schering Pharma AG Thienopyrimidylamine als Modulatoren des EP2-Rezeptors
EP2611812A1 (en) * 2010-09-01 2013-07-10 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
CN103242341B (zh) * 2013-04-19 2015-12-09 中国科学院广州生物医药与健康研究院 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用
CA2973949C (en) * 2015-01-16 2023-07-11 The General Hospital Corporation Compounds for improving mrna splicing
GB201700814D0 (en) * 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
WO2018151326A1 (ja) * 2017-02-20 2018-08-23 国立大学法人京都大学 スプライシング異常に起因する遺伝性疾病のための医薬組成物及び治療方法
SG11202108519TA (en) * 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) * 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia

Also Published As

Publication number Publication date
AU2020402717A1 (en) 2022-06-23
BR112022011364A2 (pt) 2022-08-23
WO2021118929A1 (en) 2021-06-17
JP2025133750A (ja) 2025-09-11
CO2022008195A2 (es) 2022-07-29
CL2022001523A1 (es) 2023-03-31
US20230057568A1 (en) 2023-02-23
JP2023506488A (ja) 2023-02-16
CA3160053A1 (en) 2021-06-17
PE20221581A1 (es) 2022-10-06
MX2022007094A (es) 2022-07-11
IL293764A (en) 2022-08-01
CN115209955A (zh) 2022-10-18
EP4072677A1 (en) 2022-10-19

Similar Documents

Publication Publication Date Title
KR102907028B1 (ko) 가족성 자율신경실조증 치료를 위한 티오에노[3,2-b]피리딘-7-아민 화합물
US9221809B2 (en) Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
KR20250035623A (ko) 척추소뇌성 운동실조증 유형 3을 치료하기 위한 화합물
US20120065188A1 (en) Substituted heterocyclic derivatives and their pharmaceutical use and compositions
TWI765323B (zh) 抗流感病毒化合物及其製備方法和用途
KR20210125026A (ko) Tlr7 작용제로서의 이미다조[2,1-f][1,2,4]트리아진-4-아민 유도체
JP2025133750A (ja) 家族性自律神経失調症を処置するための化合物
AU2014234907B2 (en) Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors
EP4423068A1 (en) Rxfp1 agonists
CN114555592B (zh) 作为m4激动剂的2-氮杂螺[3.4]辛烷衍生物
CN114787167B (zh) 用于治疗寄生虫病的化合物及组合物
CN110218218B (zh) 苯并呋喃类衍生物、其制备方法及其在医药上的应用
WO2024249252A1 (en) Methods of using apol1 inhibitors
WO2025049419A1 (en) Pyrazolyl compounds as emopamil binding protein inhibitors
US20260055083A1 (en) Apol1 inhibitors and methods of use
CN115003671A (zh) Jnk抑制剂、其药物组合物和用途
HK40065747A (zh) 用於治疗家族性自主神经功能障碍的噻吩并[3，2-b]吡啶-7-胺化合物
BR122024013729A2 (pt) Compostos de tieno[3,2-b]piridin-7-amina, seus usos no tratamento de disautonomia familiar e composição farmacêutica compreendendo os mesmos

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20220608

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220713

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240830

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241111

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D